Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04787471

Corneal Crosslinking for Treatment of Corneal Neovascularization

The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Corneal Neovascularization Corneal Diseases Eye Diseases Metaplasia Neovascularization, Pathologic Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Price Vision Group

Indianapolis, Indiana, 46260, United States

Location status: Recruiting

Location contact

Francis Price, Jr., MD

PRINCIPAL_INVESTIGATOR

Marianne Price, PhD

CONTACT

[email protected]

317-814-2990

Matthew Feng, MD

SUB_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age or older
  • With active inflammation or infection causing vascularization and possibly melting of the cornea, or vessels extending into the cornea causing lipid deposition, or vascularization that could significantly increase the risk of rejection of a current or planned corneal transplant, or vessels that continue to extend into the cornea despite topical treatment with corticosteroids.
  • Signed written informed consent.

Exclusion criteria

  • Known sensitivity to treatment medications
  • Current condition that in the investigator's opinion could compromise safety or data integrity.
  • Pregnancy (including plan to become pregnant) or lactation during the course of the study

Treatment and study plan

30 minute photoactivation of riboflavin 0.1%

Combination Product

Use of riboflavin 0.1% eye drops and 3mW/cm2 UVA light for 30 minutes

10 minute photoactivation of riboflavin 0.1%

Combination Product

Use of riboflavin 0.1% eye drops and 9mW/cm2 UVA light for 10 minutes

Primary outcomes

  1. corneal neovascularization as a proportion of the total corneal area

    Time frame: 6 months

    the cornea will be photographed and morphometric image analysis software will be used to measure corneal neovascularization as a proportion of the total corneal area. The proportion measured at baseline will be compared with the proportion measured at 6 months after treatment.

Study contacts

Contact information is provided by the study sponsor or research team.

Marianne Price, PhD

CONTACT

[email protected]

317-814-2990

Sponsors and collaborators

Lead sponsor

Price Vision Group

Industry

Collaborators

  • Cornea Research Foundation of America

Registry information

Official study title

Randomized Comparison of Standard vs. Accelerated Corneal Crosslinking for Treatment of Corneal Neovascularization With or Without Concomitant Inflammation and/or Infection

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Mar 8, 2021
Registry last updated
Jul 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.